Unichem Labs: Q3 FY26 Results & Appoints Dr. Swati Patankar as Independent Director
Unichem Laboratories reported Q3 FY26 results with consolidated revenue at ₹521.17 crore and profit after tax at ₹264.29 crore. Standalone revenue was ₹314.90 crore, with profit after tax at ₹216.11 crore. The company also appointed Dr. (Ms.) Swati Patankar as Non-Executive Independent Director for five years, effective February 5, 2026.
The appointment of an independent director is a governance positive. The substantial increase in profit, while positive, is somewhat offset by a decrease in revenue compared to the previous year's quarter, leading to a medium impact.
The appointment of an experienced independent director and a significant increase in profit after tax for both consolidated and standalone results contribute to a positive sentiment.
Unichem Laboratories Limited announced its Unaudited Financial Results for the third quarter and nine months ended December 31, 2025. The Board of Directors, in its meeting held on February 5, 2026, approved these results. Additionally, based on the recommendation of the Nomination & Remuneration Committee, the Board approved the appointment of Dr. (Ms.) Swati Patankar as a Non-Executive Independent Director for a term of five consecutive years, effective February 5, 2026, subject to shareholder approval.
Dr. Patankar brings over 35 years of experience and holds a Ph.D. in Molecular Microbiology. She is a Professor at IIT, Bombay, and has administrative experience as Dean (International Relations) and a board member at IIT Bombay. Her expertise spans academic, mentoring, regulatory, research & development, technical, and medical sciences. She has also been involved with the World Health Organization (WHO) and various Indian research institutions. Her appointment includes terms on the Audit Committee, Nomination & Remuneration Committee, and Stakeholders’ Relationship Committee.
The financial results for the quarter ended December 31, 2025, show consolidated revenue from operations at ₹521.17 crore, a decrease from ₹578.96 crore in the previous quarter and ₹533.09 crore in the corresponding quarter of the previous year. Profit after tax for the quarter was ₹264.29 crore, a significant increase from ₹(11.89) crore in the previous quarter and ₹57.85 crore in the same quarter last year. The nine-month period ended December 31, 2025, reported consolidated revenue from operations of ₹1,626.73 crore and a profit after tax of ₹241.93 crore.
Standalone results for the quarter ended December 31, 2025, show revenue from operations at ₹314.90 crore, a decrease from ₹356.90 crore in the previous quarter and ₹447.83 crore in the corresponding quarter of the previous year. Standalone profit after tax for the quarter was ₹216.11 crore, a substantial increase from ₹(39.93) crore in the previous quarter and ₹46.89 crore in the same quarter last year. The nine-month period ended December 31, 2025, reported standalone revenue from operations of ₹1,056.05 crore and a profit after tax of ₹174.33 crore.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.